Hoppa till innehål
banner-mesenkia-8

Almi Invest Invests in Mesenkia Therapeutics

New investment from Almi Invest

Mesenkia Therapeutics has received an investment from Almi Invest as part of a financing round totaling SEK 5.6 million.

The investment will support the continued development of Mesenkia’s novel therapeutic approach for glioblastoma and marks an important milestone for the company.

Read the full press release below for more information about the investment, the financing round, and Mesenkia’s continued development.

More news

Meet our CEO and learn more about our groundbreaking antibody technology and investment opportunity in one of our four investor ...

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) and Mesenkia Therapeutics announced today that the companies have signed a research collaboration ...

Researchers have identified HVEM as a promising therapeutic target in mesenchymal glioblastoma...